Neonatal iron supplementation potentiates oxidative stress, energetic dysfunction and neurodegeneration in the R6/2 mouse model of Huntington's disease

Redox Biology

Volumn 4, Issue , 2015, Pages 363-374

  Berggren, Kiersten L ^a   Chen, Jianfang ^a   Fox, Julia ^a   Miller, Jonathan ^a   Dodds, Lindsay ^a   Dugas, Bryan ^a   Vargas, Liset ^a   Lothian, Amber ^b   McAllum, Erin ^b   Volitakis, Irene ^b   Roberts, Blaine ^b   Bush, Ashley I ^b   Fox, Jonathan H ^a  

^a UNIVERSITY OF WYOMING   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Gene environment interaction; Huntington's; Iron; Neurodegeneration; Oxidative stress; Stereology

Indexed keywords

BIOLOGICAL MARKER; GLUTATHIONE; HUNTINGTIN; IRON; LACTIC ACID; CARBONYL IRON; GLUTATHIONE DISULFIDE; IRON DERIVATIVE; SEROTONIN TRANSPORTER; SLC6A4 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ATROPHY; BRAIN LEVEL; BRAIN SIZE; CORPUS STRIATUM; DIET SUPPLEMENTATION; ENERGY TRANSFER; HUNTINGTIN GENE; HUNTINGTON CHOREA; MOUSE; NERVE DEGENERATION; NEWBORN; NONHUMAN; OXIDATIVE STRESS; WILD TYPE; ADVERSE EFFECTS; AGONISTS; ANIMAL; ANIMAL BEHAVIOR; DIETARY SUPPLEMENT; DISEASE MODEL; DRUG EFFECTS; ENERGY METABOLISM; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; MOTOR CORTEX; NERVE CELL; PATHOLOGY; PHENOTYPE; ROTAROD TEST; TRANSGENIC MOUSE;

MUS;

ANIMALS; ANIMALS, NEWBORN; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; FEMALE; GENE EXPRESSION; GLUTATHIONE DISULFIDE; HUMANS; HUNTINGTON DISEASE; IRON COMPOUNDS; MICE; MICE, TRANSGENIC; MOTOR CORTEX; NEURONS; OXIDATIVE STRESS; PHENOTYPE; ROTAROD PERFORMANCE TEST; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84923008546     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2015.02.002     Document Type: Article

References (48)

1. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993, 72(6):971-983. THDCRG. http://www.ncbi.nlm.nih.gov/pubmed/8458085, 10.1016/0092-8674(93)90585-E.
2. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. Journal of Neuropathology and Experimental Neurology 1985, 44(6):559-577. http://www.ncbi.nlm.nih.gov/pubmed/2932539, 10.1097/00005072-198511000-00003.
3. Snell R.G., MacMillan J.C., Cheadle J.P., Fenton I., Lazarou L.P., Davies P., MacDonald M.E., Gusella J.F., Harper P.S., Shaw D.J. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nature Genetics 1993, 4(4):393-397. http://www.ncbi.nlm.nih.gov/pubmed/8401588, 10.1038/ng0893-393.
4. Rosenblatt A., Kumar B.V., Mo A., Welsh C.S., Margolis R.L., Ross C.A. Age, CAG repeat length, and clinical progression in Huntington's disease. Movement Disorders: Official Journal of the Movement Disorder Society 2012, 27(2):272-276. http://www.ncbi.nlm.nih.gov/pubmed/22173986, 10.1002/mds.24024.
5. Arning L., Epplen J.T. Genetic modifiers of Huntington's disease: beyond CAG. Future Neurology 2012, 7(1):93-109. 10.2217/fnl.11.65.
6. Dunah A.W., Jeong H., Griffin A., Kim Y.M., Standaert D.G., Hersch S.M., Mouradian M.M., Young A.B., Tanese N., Krainc D. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 2002, 296(5576):2238-2243. http://www.ncbi.nlm.nih.gov/pubmed/11988536, 10.1126/science.1072613.
7. Cui L., Jeong H., Borovecki F., Parkhurst C.N., Tanese N., Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006, 127(1):59-69. http://www.ncbi.nlm.nih.gov/pubmed/17018277, 10.1016/j.cell.2006.09.015.
8. Valencia A., Sapp E., Kimm J.S., McClory H., Reeves P.B., Alexander J., Ansong K.A., Masso N., Frosch M.P., Kegel K.B., Li X., DiFiglia M. Elevated NADPH oxidase activity contributes to oxidative stress and cell death in Huntington's disease. Human Molecular Genetics 2013, 22(6):1112-1131. http://www.ncbi.nlm.nih.gov/pubmed/23223017, 10.1093/hmg/dds516.
9. Rosas H.D., Chen Y.I., Doros G., Salat D.H., Chen N.K., Kwong K.K., Bush A., Fox J., Hersch S.M. Alterations in brain transition metals in Huntington disease: an evolving and intricate story. Archives of Neurology 2012, 69:887-893. http://www.ncbi.nlm.nih.gov/pubmed/22393169, 10.1001/archneurol.2011.2945.
10. Chen J., Marks E., Lai B., Zhang Z., Duce J.A., Lam L.Q., Volitakis I., Bush A.I., Hersch S., Fox J.H. Iron accumulates in Huntington's disease neurons: protection by deferoxamine. PLOS One 2013, 8(10):e77023. http://www.ncbi.nlm.nih.gov/pubmed/24146952, 10.1371/journal.pone.0077023.
11. Dexter D.T., Carayon A., Javoy-Agid F., Agid Y., Wells F.R., Daniel S.E., Lees A.J., Jenner P., Marsden C.D. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991, 114(4):1953-1975. http://www.ncbi.nlm.nih.gov/pubmed/1832073, 10.1093/brain/114.4.1953.
12. Fenton H.J.H. Oxidation of tartaric acid in presence of iron. Journal of the Chemical Society, Transactions 1894, 65:899-911. 10.1039/ct8946500899.
13. Ward R.J., Zucca F.A., Duyn J.H., Crichton R.R., Zecca L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurology 2014, 13(10):1045-1060. http://www.ncbi.nlm.nih.gov/pubmed/25231526, 10.1016/S1474-4422(14)70117-6.
14. Peers C., Boyle J.P. Oxidative modulation of K(+) channels in the central nervous system in neurodegenerative diseases and aging. Antioxidants & Redox Signaling 2014, http://www.ncbi.nlm.nih.gov/pubmed/25333910, 10.1089/ars.2014.6007.
15. Lizama-Manibusan B., McLaughlin B. Redox modification of proteins as essential mediators of CNS autophagy and mitophagy. FEBS Letters 2013, 587(15):2291-2298. http://www.ncbi.nlm.nih.gov/pubmed/23773928, 10.1016/j.febslet.2013.06.007.
16. Ganz T. Systemic iron homeostasis. Physiological Reviews 2013, 93(4):1721-1741. http://www.ncbi.nlm.nih.gov/pubmed/24137020, 10.1152/physrev.00008.2013.
17. Cherny R.A., Ayton S., Finkelstein D.I., Bush A.I., McColl G., Massa S.M. PBT2 reduces toxicity in a C. elegans model of polyQ aggregation and extends lifespan, reduces striatal atrophy and improves motor performance in the R6/2 mouse model of Huntington's disease. Journal of Huntington's Disease 2012, 1(2):211-219. http://www.ncbi.nlm.nih.gov/pubmed/25063332, 10.3233/JHD-120029.
18. Fredriksson A., Schröder N., Eriksson P., Izquierdo I., Archer T. Neonatal iron exposure induces neurobehavioral dysfunctions in adult mice. Toxicology and Applied Pharmacology 1999, 159(1):25-30. http://www.ncbi.nlm.nih.gov/pubmed/10448122, 10.1006/taap.1999.8711.
19. De Lima M.N., Laranja D.C., Caldana F., Grazziotin M.M., Garcia V.A., Dal-Pizzol F., Bromberg E., Schröder N. Selegiline protects against recognition memory impairment induced by neonatal iron treatment. Experimental Neurology 2005, 196(1):177-183. http://www.ncbi.nlm.nih.gov/pubmed/16122736, 10.1016/j.expneurol.2005.07.017.
20. Kaur D., Peng J., Chinta S.J., Rajagopalan S., Di Monte D.A., Cherny R.A., Andersen J.K. Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiology of Aging 2007, 28(6):907-913. http://www.ncbi.nlm.nih.gov/pubmed/16765489, 10.1016/j.neurobiolaging.2006.04.003.
21. Yu S., Feng Y., Shen Z., Li M. Diet supplementation with iron augments brain oxidative stress status in a rat model of psychological stress. Nutrition 2011, 27:1048-1052. http://www.ncbi.nlm.nih.gov/pubmed/21454054, 10.1016/j.nut.2010.11.007.
22. Rice D., Barone S. Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environmental Health Perspectives 2000, 108(Suppl. 3):511-533. http://www.ncbi.nlm.nih.gov/pubmed/10852851.
23. Lu Z., Marks E., Chen J., Moline J., Barrows L., Raisbeck M., Volitakis I., Cherny R.A., Chopra V., Bush A.I., Hersch S., Fox J.H. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model. Neurobiology of Disease 2014, 71:34-42. 10.1016/j.nbd.2014.06.022.
24. Chopra V., Fox J.H., Lieberman G., Dorsey K., Matson W., Waldmeier P., Housman D.E., Kazantsev A., Young A.B., Hersch S. A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(42):16685-16689. http://www.ncbi.nlm.nih.gov/pubmed/17925440, 10.1073/pnas.0707842104.
25. Fox J.H., Barber D.S., Singh B., Zucker B., Swindell M.K., Norflus F., Buzescu R., Chopra R., Ferrante R.J., Kazantsev A., Hersch S.M. Cystamine increases l-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation. Journal of Neurochemistry 2004, 91(2):413-422. http://www.ncbi.nlm.nih.gov/pubmed/15447674, 10.1111/j.1471-4159.2004.02726.x.
26. Fox J.H., Kama J.A., Lieberman G., Chopra R., Dorsey K., Chopra V., Volitakis I., Cherny R.A., Bush A.I., Hersch S. Mechanisms of copper ion mediated Huntington's disease progression. PLOS One 2007, 2(3):e334. http://www.ncbi.nlm.nih.gov/pubmed/17396163, 10.1371/journal.pone.0000334.
27. Maynard C.J., Cappai R., Volitakis I., Cherny R.A., Masters C.L., Li Q.X., Bush A.I. Gender and genetic background effects on brain metal levels in APP transgenic and normal mice: implications for Alzheimer beta-amyloid pathology. Journal of Inorganic Biochemistry 2006, 100(5-6):952-962. http://www.ncbi.nlm.nih.gov/pubmed/16574231, 10.1016/j.jinorgbio.2006.02.010.
28. Hare D.J., Grubman A., Ryan T.M., Lothian A., Liddell J.R., Grimm R., Matsuda T., Doble P.A., Cherny R.A., Bush A.I., White A.R., Masters C.L., Roberts B.R. Profiling the iron, copper and zinc content in primary neuron and astrocyte cultures by rapid online quantitative size exclusion chromatography-inductively coupled plasma-mass spectrometry. Metallomics: Integrated Biometal Science 2013, 5(12):1656-1662. http://www.ncbi.nlm.nih.gov/pubmed/24132241, 10.1039/c3mt00227f.
29. Roberts B.R., Lim N.K., McAllum E.J., Donnelly P.S., Hare D.J., Doble P.A., Turner B.J., Price K.A., Lim S.C., Paterson B.M., Hickey J.L., Rhoads T.W., Williams J.R., Kanninen K.M., Hung L.W., Liddell J.R., Grubman A., Monty J.F., Llanos R.M., Kramer D.R., Mercer J.F., Bush A.I., Masters C.L., Duce J.A., Li Q.X., Beckman J.S., Barnham K.J., White A.R., Crouch P.J. Oral treatment with Cu(II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis. Journal of Neuroscience 2014, 34(23):8021-8031. http://www.ncbi.nlm.nih.gov/pubmed/24899723, 10.1523/JNEUROSCI.4196-13.2014.
30. Slow E.J., van Raamsdonk J., Rogers D., Coleman S.H., Graham R.K., Deng Y., Oh R., Bissada N., Hossain S.M., Yang Y.Z., Li X.J., Simpson E.M., Gutekunst C.A., Leavitt B.R., Hayden M.R. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Human Molecular Genetics 2003, 12(13):1555-1567. http://www.ncbi.nlm.nih.gov/pubmed/12812983, 10.1093/hmg/ddg169.
31. Fox J.H., Connor T., Chopra V., Dorsey K., Kama J.A., Bleckmann D., Betschart C., Hoyer D., Frentzel S., Difiglia M., Paganetti P., Hersch S.M. The mTOR kinase inhibitor everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease. Molecular Neurodegeneration 2010, 5:26. http://www.ncbi.nlm.nih.gov/pubmed/20569486, 10.1186/1750-1326-5-26.
32. Van Raamsdonk J.M., Pearson J., Slow E.J., Hossain S.M., Leavitt B.R., Hayden M.R. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. Journal of Neuroscience 2005, 25(16):4169-4180. http://www.ncbi.nlm.nih.gov/pubmed/15843620, 10.1523/JNEUROSCI.0590-05.2005.
33. Dodds L., Chen J., Berggren K., Fox J. Characterization of striatal neuronal loss and atrophy in the R6/2 mouse model of Huntington's disease. PLoS Currents 2014, 6. http://www.ncbi.nlm.nih.gov/pubmed/24459614, 10.1371/currents.hd.48727b68b39b82d5fe350f753984bcf9.
34. Scherzinger E., Lurz R., Turmaine M., Mangiarini L., Hollenbach B., Hasenbank R., Bates G.P., Davies S.W., Lehrach H., Wanker E.E. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 1997, 90(3):549-558. http://www.ncbi.nlm.nih.gov/pubmed/9267034, 10.1016/S0092-8674(00)80514-0.
35. Duce J.A., Tsatsanis A., Cater M.A., James S.A., Robb E., Wikhe K., Leong S.L., Perez K., Johanssen T., Greenough M.A., Cho H.H., Galatis D., Moir R.D., Masters C.L., McLean C., Tanzi R.E., Cappai R., Barnham K.J., Ciccotosto G.D., Rogers J.T., Bush A.I. Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 2010, 142(6):857-867. http://www.ncbi.nlm.nih.gov/pubmed/20817278, 10.1016/j.cell.2010.08.014.
36. McCarthy R.C., Park Y.H., Kosman D.J. sAPP modulates iron efflux from brain microvascular endothelial cells by stabilizing the ferrous iron exporter ferroportin. EMBO Reports 2014, 15(7):809-815. http://www.ncbi.nlm.nih.gov/pubmed/24867889, 10.15252/embr.201338064.
37. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87(3):493-506. http://www.ncbi.nlm.nih.gov/pubmed/8898202, 10.1016/S0092-8674(00)81369-0.
38. Radlowski E.C., Johnson R.W. Perinatal iron deficiency and neurocognitive development. Frontiers in Human Neuroscience 2013, 7:585. http://www.ncbi.nlm.nih.gov/pubmed/24065908, 10.3389/fnhum.2013.00585.
39. Collard K.J. Iron homeostasis in the neonate. Pediatrics 2009, 123(4):1208-1216. http://www.ncbi.nlm.nih.gov/pubmed/19336381, 10.1542/peds.2008-1047.
40. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB Journal 2008, 22(3):659-661. http://www.ncbi.nlm.nih.gov/pubmed/17942826, 10.1096/fj.07-9574LSF.
41. Clancy B., Finlay B.L., Darlington R.B., Anand K.J. Extrapolating brain development from experimental species to humans. Neurotoxicology 2007, 28(5):931-937. http://www.ncbi.nlm.nih.gov/pubmed/17368774, 10.1016/j.neuro.2007.01.014.
42. Arrasate M., Mitra S., Schweitzer E.S., Segal M.R., Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004, 431(7010):805-810. http://www.ncbi.nlm.nih.gov/pubmed/15483602, 10.1038/nature02998.
43. Uttara B., Singh A.V., Zamboni P., Mahajan R.T. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Current Neuropharmacology 2009, 7(1):65-74. http://www.ncbi.nlm.nih.gov/pubmed/19721819, 10.2174/157015909787602823.
44. Ribeiro M., Rosenstock T.R., Cunha-Oliveira T., Ferreira I.L., Oliveira C.R., Rego A.C. Glutathione redox cycle dysregulation in Huntington's disease knock-in striatal cells. Free Radical Biology & Medicine 2012, 53(10):1857-1867. http://www.ncbi.nlm.nih.gov/pubmed/22982598, 10.1016/j.freeradbiomed.2012.09.004.
45. Jenkins B.G., Koroshetz W.J., Beal M.F., Rosen B.R. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology 1993, 43(12):2689-2695. http://www.ncbi.nlm.nih.gov/pubmed/8255479, 10.1212/WNL.43.12.2689.
46. Fredriksson A., Schröder N., Eriksson P., Izquierdo I., Archer T. Neonatal iron potentiates adult MPTP-induced neurodegenerative and functional deficits. Parkinsonism & Related Disorders 2001, 7(2):97-105. http://www.ncbi.nlm.nih.gov/pubmed/11248590, 10.1016/S1353-8020(00)00028-6.
47. Millen A.E., Dodd K.W., Subar A.F. Use of vitamin, mineral, nonvitamin, and nonmineral supplements in the United States: the 1987, 1992, and 2000 National Health Interview Survey results. Journal of the American Dietetic Association 2004, 104(6):942-950. http://www.ncbi.nlm.nih.gov/pubmed/15175592, 10.1016/j.jada.2004.03.022.
48. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium and Zinc 2001, Institute of Medicine Food and Nutrition Board, National Academies Press, Washington, DC.